Herman Nilsson‐Ehle

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2008 · 619 citations · Full text

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Eva Hellström-Lindberg, Tomas Ahlgren, Yves Béguin et al. · Blood · 1998 · 306 citations · Full text

Nordic <scp>MCL</scp>2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <scp>BEAM</scp> or <scp>BEAC</scp> + autologous stem‐cell support: still very long survival but late relapses do occur

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · British Journal of Haematology · 2012 · 265 citations

Cell Therapy, Immunology, Pathology +22

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau

Christian Winther Eskelund, Arne Kolstad, Mats Jerkeman et al. · British Journal of Haematology · 2016 · 207 citations · Full text

Immunology, Pathology, Hematological Malignancy +16

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2009 · 184 citations